AstraZeneca Pharma India Limited reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2016. For the quarter, the company reported net sales/income from operations (net of excise duty) of INR 1,411.234 million against INR 1,445.608 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 109.220 million against INR 71.947 million for the same period a year ago. Profit from ordinary activities before tax was INR 207.547 million against INR 86.742 million for the same period a year ago. Net income was INR 159.629 million against INR 86.742 million for the same period a year ago. Basic and diluted EPS was INR 6.39 against INR 3.47 for the same period a year ago. For the nine months, the company reported net sales/income from operations (net of excise duty) of INR 4,153.594 million against INR 3,929.450 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 219.849 million against INR 0.219 million for the same period a year ago. Profit from ordinary activities before tax was INR 351.961 million against INR 47.017 million for the same period a year ago. Basic and diluted EPS was INR 10.93 against INR 1.88 for the same period a year ago. Net income was INR 273.176 million against INR 47.017 million for the same period a year ago.